<DOC>
	<DOCNO>NCT01678534</DOCNO>
	<brief_summary>Phase IIa clinical trial , pilot , single centre , prospective , randomize , double-blind , placebo-controlled , sequential inclusion patient</brief_summary>
	<brief_title>Reparative Therapy Acute Ischemic Stroke With Allogenic Mesenchymal Stem Cells From Adipose Tissue , Safety Assessment , Randomised , Double Blind Placebo Controlled Single Center Pilot Clinical Trial</brief_title>
	<detailed_description>20 Patients present moderate-severe acute ischemic stroke randomize 1:1 proportion intravenous treatment allogeneic stem cell adipose tissue placebo ( vehicle ) .</detailed_description>
	<mesh_term>Stroke</mesh_term>
	<mesh_term>Ischemia</mesh_term>
	<mesh_term>Cerebral Infarction</mesh_term>
	<criteria>Inclusion criterion : Male female acute ischemic patient age 6080 year symptoms acute cerebral infarction le 12h stroke onset . If time symptom onset unknown , shall refer last time patient asymptomatic see . Patients treat within two week onset stroke symptom . Patients measurable focal neurological must persist time treatment without clinically meaningful improvement . Patients must computerize tomography ( CT ) / magnetic resonance imaging ( MRI ) compatible clinical diagnosis acute ischemic stroke territory middle cerebral artery include study . Patients must score NIH Stroke Scale 820 , least 2 point Sections 5 6 ( motor deficit ) time inclusion . Immediately ( i.e . minute ) stroke , patient score mRS ≤ 1 ( symptom significant disability despite symptom , able perform everyday task activity ) . Women childbearing age negative pregnancy test perform prior inclusion . Obtaining informed consent sign ( detailed explanation nature purpose study , patient guardian legal representative must give consent participate signing informed consent document ) . Assent relative career patient unable give meaningful consent ( e.g . case dysphasia , confusion , reduce conscious level ) . Exclusion criterion : Comatose patient . Patients score 2 item 1a NIHSS relate degree awareness . Evidence neuroimaging ( CT MRI ) brain tumour , cerebral oedema midline shift clinically significant compression ventricle , cerebellar infarction brainstem , intraventricular , intracerebral subarachnoid haemorrhage . Current drug alcohol use dependence , opinion site investigator , would interfere adherence study requirements.· Active infectious disease , include HIV , hepatitis B , Hepatitis C , etc . Preexisting dementia . Specify health status clinical condition ( e.g. , life expectancy , coexist disease ) characteristic preclude appropriate diagnosis , treatment followup trial . Patients participate another clinical trial . Inability unwillingness individual legal guardian/representative give write informed consent .</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Cerebral infarction</keyword>
	<keyword>Cellular therapy</keyword>
</DOC>